Fig. 2

Percentage of patients shifting from CM to EM frequency during the 12-month study. The percentage of patients is shown who maintained a shift to EM frequency from CM for ≥ 3 consecutive months on galcanezumab during the 12-month study (double-blind and OLE periods) (A) and who maintained that ≥ 3-month shift to EM frequency until their endpoint (B). Bars are labeled based on the randomized treatment group assigned at the start of the 3-month double-blind period. Patients who were on placebo during the double-blind period and received galcaneumab during the OLE period only have data from the OLE included in this analysis and are labelled as “From previous placebo.” The “All galcanezumab” group includes all patients who received galcanezumab in either the double-blind or OLE periods, regardless of previous randomized group. EM is defined as < 8 migraine headache days/month or < 15 headache days/month, LFEM as < 8 migraine headache days/month; and VLFEM as < 4 migraine headache days/month. Thus, EM includes LFEM and VLFEM, and LFEM includes VLFEM. Abbreviations: EM, episodic migraine, LFEM, low frequency episodic migraine; OLE, open-label extension; VLFEM, very low frequency episodic migraine